Bankruptcy: Arch Therapeutics, Inc.

Add to your watchlist
Back to List of Bankruptcies and Liquidations

Form Type: 8-K

Filing Date: 2025-05-23

Corporate Action: Bankruptcy

Type: Update

Accession Number: 000164117225012288

Filing Summary: On April 18, 2025, Arch Therapeutics, Inc. and its subsidiary Arch Biosurgery, Inc. filed for Chapter 11 bankruptcy protection in Massachusetts. The company is currently operating as a debtor-in-possession. A stalking horse bid has been accepted for the majority of its assets, with potential cancellation of all equity securities and no recovery expected for shareholders. On May 23, 2025, the court approved postpetition financing and plans for a Chapter 11 plan of liquidation involving a Section 363 sale of assets. A hearing to approve the asset sale is scheduled for June 20, 2025. The company has defaulted on its convertible notes and faced difficulties with listing requirements, resulting in a reclassification of its securities on the OTC Markets. The company has also announced the resignation of its accounting firm, Weinberg & Company, P.A., and is struggling to fulfill its reporting obligations due to resource constraints.

Additional details:

Item Number: 1.03

Bankruptcy Case Number: 25-40409


Item Number: 1.03

Court District: District of Massachusetts


Item Number: 1.03

Stalking Horse Bid Acceptance: yes


Item Number: 1.03

Anticipated Outcome For Shareholders: no recovery


Item Number: 1.03

Financing Order Approved: yes


Item Number: 1.03

Scheduled Hearing Date: 2025-06-20


Item Number: 2.04

Event Of Default: yes


Item Number: 3.01

Market Reclassification: OTC Expert Market


Item Number: 4.01

Independent Accountant: Weinberg & Company, P.A.


Item Number: 8.01

Non Compliance Reason: insufficient personnel and financial resources


Comments

No comments yet. Be the first to comment!